Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials

Persistence Evaluation and Response Study for Immunotherapy Safety Tracking of Participants Who Receive an AvenCell CAR-T Cell Therapy

The goal of this clinical study is to learn more about the long-term safety, effectiveness and prolonged action of patients who participated in an AvenCell-sponsored clinical trial and received treatment with AvenCell's UniCAR or RevCAR platforms.

To assess the incidence and severity of delayed serious adverse events (SAEs) possibly related to AVC-CAR-T cell therapy and AEs of special interest (AESIs), including secondary malignancies, neurologic disorders, rheumatologic or other autoimmune disorders, newly diagnosed serious hematologic disorders, severe infections, as well as pregnancy and newborn health complications where observed.

Inclusion Criteria:

1. Participant who received an AVC-CAR-T cell therapy within an AVC-sponsored clinical trial.
2. Participant signed written informed consent for the AVC-PERSIST study.

Exclusion Criteria:

1. Participant is unable to provide written informed consent.
2. Participant is unable to comply with study requirements in the eyes of the Investigator.